Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight loss has captured more public attention.

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

The researchers found that low-dose semaglutide (0.25 mg/week for four weeks, 0.5 mg/week for four weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment ...

Ozempic (semaglutide) is a prescription drug used ... your doctor may increase your dose by up to 1 mg. Your dosage adjustment will depend on your current dosage and how well it’s working ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

By removing both semaglutide and tirzepatide (the actives in Wegovy and Zepbound, respectively) from its drug shortage list, the agency is cutting off the primary legal route that allows ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Until recently, semaglutide injection products had been in short supply ... can receive Wegovy (2.5mg, 0.5mg, 1mg, 1.7mg, and 2.4mg) at a reduced cost of $499 per month. According to the Company, the ...

Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...

Results showed 51% of people treated with 0.5mg semaglutide compared with 36% of those treated with 0.75mg dulaglutide reached the treatment goal, and 68% of people on the 1mg semaglutide dose ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...